PANTHERx® Rare Pharmacy Selected by Alnylam Pharmaceuticals to Distribute GIVLAARI™ (givosiran)
PR Newswire | December 12, 2019
PANTHERx® Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals as a very limited distribution partner for the novel drug GIVLAARI™ (givosiran). GIVLAARI is the first and only FDA-approved medicine indicated for the treatment of adults with Acute Hepatic Porphyria (AHP). GIVLAARI becomes the second RNAi therapeutic from Alnylam approved by the FDA in the last 16 months and the first-ever approved GalNAc-Conjugate RNA therapeutic, a landmark in the advancement of precision genetic medicines. The FDA approval of GIVLAARI was received less than four months after the New Drug Application (NDA) filing acceptance and was based on positive results from the ENVISION Phase 3 study, a randomized, double-blind, placebo-controlled,